RS-25344

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H13N5O4
Molecular Weight	375.3376
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N+](=O)C1=CC(=CC=C1)N2C(=O)N(CC3=CC=NC=C3)C(=O)C4=C2N=CC=C4

InChI

InChIKey=YLHRMVRLIOIWTO-UHFFFAOYSA-N

InChI=1S/C19H13N5O4/c25-18-16-5-2-8-21-17(16)23(14-3-1-4-15(11-14)24(27)28)19(26)22(18)12-13-6-9-20-10-7-13/h1-11H,12H2

HIDE SMILES / InChI

Molecular Formula	C19H13N5O4
Molecular Weight	375.3376
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8562314 | https://www.elsevier.com/books/phosphodiesterase-inhibitors/page/978-0-12-210720-7
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8562314 | https://www.ncbi.nlm.nih.gov/pubmed/16177223 | https://www.ncbi.nlm.nih.gov/pubmed/10079010

RS25344 is a potent and selective phosphodiesterase (PDE) 4 inhibitor. It preferentially inhibits phosphorylated PDE4D. The compound demonstrated efficacy in animal models of inflammation and anaphylaxis. RS25344 inhibited eosinophil chemotaxis, increased the progressive motility of bovine spermatozoa, inhibited leukotriene B4 biosynthesis by human polymorphonuclear leukocytes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 4D 14 Target ID: CHEMBL288 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7476886 \| https://www.ncbi.nlm.nih.gov/pubmed/8562314 \| https://www.ncbi.nlm.nih.gov/pubmed/9720765	Inhibitor 8504	9.3 null [pIC50]
Phosphodiesterase 4C 5 Target ID: CHEMBL291 Sources: https://www.elsevier.com/books/phosphodiesterase-inhibitors/page/978-0-12-210720-7	Inhibitor 8504	7.7 null [pIC50]
Phosphodiesterase 4B 11 Target ID: CHEMBL275 Sources: https://www.elsevier.com/books/phosphodiesterase-inhibitors/page/978-0-12-210720-7	Inhibitor 8504	7.5 null [pIC50]
Phosphodiesterase 4A 13 Target ID: CHEMBL254 Sources: https://www.elsevier.com/books/phosphodiesterase-inhibitors/page/978-0-12-210720-7	Inhibitor 8504	7.8 null [pIC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Inflammation 105 Sources: (1996) Phosphodiesterase Inhibitors, page 166, retrieved from: https://books.google.ru/books?id=JnDkC1H0dpAC	Primary		Preclinical	Unknown Approved Use Unknown
Anaphylaxis 47 Sources: (1996) Phosphodiesterase Inhibitors, page 166, retrieved from: https://books.google.ru/books?id=JnDkC1H0dpAC	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa.	2006-01	16177223
Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium.	2005-03-04	15611099
Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.	2004-02	14610230
Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.	2003-10	12873709
Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes.	1999-02-19	10079010
Role of phosphodiesterases in the regulation of gonadotropin- releasing hormone secretion in GT1 cells.	1998-12	9873200
Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.	1998-06	9720765
Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors.	1998-05	9647555
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.	1995-10	7476886
Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils.	1995-07	8562314

Patents

Sample Use Guides

In Vivo Use Guide

RS25344 attenuated ear oedema in mice with ED50 0.02 mg/kg RS25344 attenuated anaphylaxis in guinea pigs with ED50 0.5 mg/kg

Route of Administration: Oral

In Vitro Use Guide

3-5 uM RS25344 increased the progressive motility of bovine spermatozoa

Substance Class	Chemical Created by `admin` on `Wed Apr 02 11:13:04 GMT 2025` Edited by `admin` on `Wed Apr 02 11:13:04 GMT 2025`
Record UNII	7KKH9V6X32
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RS25344

Preferred Name

English

RS-25344

Code

English

RS25344-000

Code

English

Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-(3-nitrophenyl)-3-(4-pyridinylmethyl)-

Systematic Name

English

1-(3-Nitrophenyl)-3-(4-pyridinylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

Systematic Name

English

Code System Code Type Description

CAS

152814-89-6

Created by admin on Wed Apr 02 11:13:04 GMT 2025 , Edited by admin on Wed Apr 02 11:13:04 GMT 2025

PRIMARY

EPA CompTox

DTXSID70934606

Created by admin on Wed Apr 02 11:13:04 GMT 2025 , Edited by admin on Wed Apr 02 11:13:04 GMT 2025

PRIMARY

PUBCHEM

9842556

Created by admin on Wed Apr 02 11:13:04 GMT 2025 , Edited by admin on Wed Apr 02 11:13:04 GMT 2025

PRIMARY

FDA UNII

7KKH9V6X32

Created by admin on Wed Apr 02 11:13:04 GMT 2025 , Edited by admin on Wed Apr 02 11:13:04 GMT 2025

PRIMARY

Related Record Type Details


					7KKH9V6X32

RS-25344

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides